Standard BioTools (LAB) to Release Quarterly Earnings on Wednesday

Standard BioTools (NASDAQ:LAB) will be issuing its quarterly earnings data after the market closes on Wednesday, October 30th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Standard BioTools has set its FY 2024 guidance at EPS.Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Standard BioTools (NASDAQ:LAB) last announced its earnings results on Wednesday, July 31st. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. The firm had revenue of $37.21 million for the quarter, compared to analysts’ expectations of $48.15 million. Standard BioTools had a negative return on equity of 43.45% and a negative net margin of 87.05%. On average, analysts expect Standard BioTools to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Standard BioTools Stock Performance

Shares of NASDAQ LAB opened at $1.84 on Wednesday. The stock has a fifty day moving average price of $1.93 and a two-hundred day moving average price of $2.14. Standard BioTools has a 1 year low of $1.21 and a 1 year high of $3.04. The firm has a market cap of $681.57 million, a P/E ratio of -1.82 and a beta of 1.58.

Wall Street Analyst Weigh In

Separately, TD Cowen decreased their price target on shares of Standard BioTools from $3.50 to $2.75 and set a “buy” rating on the stock in a research report on Thursday, August 1st.

Insider Activity at Standard BioTools

In other news, Director Casdin Partners Master Fund, L purchased 1,200,000 shares of Standard BioTools stock in a transaction dated Wednesday, August 14th. The stock was acquired at an average cost of $1.59 per share, for a total transaction of $1,908,000.00. Following the acquisition, the director now directly owns 51,775,821 shares in the company, valued at $82,323,555.39. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders bought 5,117,508 shares of company stock valued at $8,662,080. Insiders own 53.10% of the company’s stock.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.